LOS ANGELES--(BUSINESS WIRE)--Lundin Law PC announces a class action lawsuit has been filed against Eagle Pharmaceuticals Inc. ("Eagle" or the "Company") (Nasdaq: EGRX) concerning possible violations of federal securities laws between February 23, 2016 and March 18, 2016 (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the August 1, 2016 lead plaintiff motion deadline.
No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
According to the complaint, the Company made misrepresentations about the FDA approval process for its new anticoagulant drug, KANGIO™. Specifically, on February 25, 2016, the Company’s CEO stated, regarding the pending New Drug Application (“NDA”) for KANGIO™, "We have been interacting with FDA and we are preparing for launch, everything seems to be on track for a March 19 approval, and we anticipate shipping in late Q1 or early Q2." On March 18, 2016 Eagle disclosed that the FDA did not approve the NDA because it required more information about the substances used in KANGIO™. When the news was announced, shares of Eagle dropped in value significantly.
Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.